Group 1: Investor Relations Activity - The investor relations activity involved a specific audience survey with 9 investor representatives from various institutions [2] - The meeting took place on January 23, 2026, from 2:00 PM to 3:00 PM in the company conference room [2] - The company was represented by the Deputy General Manager and Board Secretary, Zeng Lei, and the Securities Affairs Representative, Gan Rong [2] Group 2: Product Development and Innovation - The execution of the national procurement for Loxoprofen Sodium Gel Patch is set to begin in February 2026, with a procurement cycle lasting until December 31, 2028 [2] - The innovative drug JIJ02 Gel is expected to complete Phase I clinical trials in the first half of 2026 and initiate Phase II trials [2][3] - The company is focusing on a comprehensive transformation towards innovative drug development, employing a strategy of multiple R&D centers and various drug forms [3] Group 3: R&D Strategy and Team Composition - The company has established dual innovation drug R&D centers in Central China and the Yangtze River Delta, leveraging regional clinical resources and cost advantages [3] - The R&D platform currently has over 40 members, including experts from drug design to clinical research, with core members experienced in clinical trials and market approvals [3] - The company is prioritizing the development of treatments for various cancers and chronic diseases, utilizing small molecules, peptide drugs, PDCs, and ADCs [3] Group 4: Market Strategy and Brand Promotion - The Ketoprofen Gel Patch was approved for market entry in 2023 and is optimistic about its market prospects, having entered the national medical insurance directory [3] - The company has developed new sales strategies and strengthened internal sales team assessments to enhance market performance [3] - The brand image of "Mr. Pain Relief" will continue to receive promotional investment through comprehensive marketing activities and patient education [4]